869886-67-9

Usage

Uses

Used in Pharmaceutical Industry:
VRT752271 is used as an anti-cancer agent for its ability to inhibit cell proliferation. It targets the ERK1/ERK2 pathway, which plays a crucial role in the regulation of cell growth and division. By inhibiting this pathway, VRT752271 can effectively suppress the growth of cancer cells and potentially lead to tumor regression.
In addition to its direct anti-cancer effects, VRT752271 may also be used in combination with other cancer therapies to enhance their efficacy and overcome drug resistance. Its reversible binding to ERK1/ERK2 allows for precise control of the inhibition, which may contribute to improved safety and tolerability in cancer treatment.

Upstream product

• 869886-90-8 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1H pyrrole-2-carboxylic acid 
• 620616-08-2 2-(S)-amino-2-(3-chloro-phenyl)-ethanol hydrochloride 
• 663611-73-2 (S)-2-amino-2-(3-chlorophenyl)ethyl-1-alcohol 
• 869886-85-1 4-iodo-1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester 
• 16110-09-1 2,5 dichloropyridine 
• 35302-72-8 pyrrol-2-yl trichloromethyl ketone 
• 869886-86-2 methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxoborolan-2-yl)-1-p-toluenesulfonyl-1H-pyrrole-2-carboxylate 
• 869886-89-5 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1-(2,4,6-trimethylbenzenesulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester 
• 869886-92-0 4-(5-chloro-2-isopropylamino-pyridin-4-yl)-1-(2,4,6-trimethyl-benzenesulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester N-oxide 
• 40740-41-8 methyl 4-iodo-1H-pyrrole-2-carboxylic acid ester 
• 405230-81-1 2,5-dichloro-4-nitropyridine-1-oxide 
• 869886-88-4 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester 
• 869886-87-3 5-chloro-4-iodo-N-isopropylpyridin-2-amine 
• 659731-48-3 5-chloro-2-fluoro-4-iodopyridine 

Downstream Products

• 1956366-10-1 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride 
• 1956366-10-1 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylicacid[1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride 

Relevant academic research and scientific papers

CRYSTALLINE FORMS OF C21H22CI2N4O2

The present invention provides crystalline forms of a compound of formula (I). Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer. It has been discovered that crystalline forms of 4-(5-Chloro-2- isopropylaminopyridin-4-yl)-1 H-pyrrole-2-carboxylic acid [1 -(3-chlorophenyl)-2- hydroxyethyl]amide can be prepared which exhibit improved properties, e.g. surprisingly improved stability and improved solubility characteristics. Thus, the present invention provides crystalline 4-(5-Chloro-2- isopropylaminopyridin-4-yl)-1H-pyrrole-2-carboxylic acid [1 -(3-chlorophenyl)-2- hydroxyethyljamide.

CRYSTALLINE C21H22C12N4O2 MALONATE

The present invention provides a malonate salt of a compound of formula (I), which is a crystalline salt. Also provided are pharmaceutical compositions that include the provided malonate salt and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.

PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO

The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.